WO2025247178 - PRMT5 INHIBITOR, AND COMPOSITION AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/247178
Publication Date
04.12.2025
International Application No.
PCT/CN2025/097306
International Filing Date
27.05.2025
Title **
[English]
PRMT5 INHIBITOR, AND COMPOSITION AND USE THEREOF
[French]
INHIBITEUR DE PRMT5, COMPOSITION ET UTILISATION ASSOCIÉES
[Chinese]
一类PRMT5抑制剂及其组合物和用途
Applicants **
ALICORN PHARMACEUTICAL CO., LTD
Inventors
LU, Pingbo
ZHU, Hui
ZHU, Di
FANG, Hao
LI, Zhouyang
CHEN, Huimin
CENG, Yue
NIU, Qingjiang
CENG, Yan
Priority Data
202410675593.5
28.05.2024
CN
202410903906.8
05.07.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2156 | |
| EPO | Filing, Examination, Granting | 16722 | |
| Japan | Filing, Examination, Granting | 2450 | |
| South Korea | Filing, Examination, Granting | 2736 | |
| USA | Filing, Examination, Granting | 5540 |
Total:
29,604
Contact Us
Abstract[English]
Provided are a PRMT5 inhibitor, and a composition and the use thereof. Specifically, the present invention relates to a PRMT5 inhibitor, and a stereoisomer thereof or a pharmaceutically acceptable salt thereof. The heterocyclic compound that inhibits PRMT5 activity has a structure as represented by formula (I). Further provided are a composition containing the compound and the use thereof as a PRMT5 inhibitor.[French]
L'invention concerne un inhibiteur de PRMT5, une composition et son utilisation. Plus particulièrement, la présente invention concerne un inhibiteur de PRMT5, et un stéréoisomère de celui-ci ou un sel pharmaceutiquement acceptable de celui-ci. Le composé hétérocyclique qui inhibe l'activité de PRMT5 a une structure telle que représentée par la formule (I). L'invention concerne en outre une composition contenant le composé et son utilisation en tant qu'inhibiteur de PRMT5.[Chinese]
提供了一类PRMT5抑制剂及其组合物和用途。具体涉及PRMT5抑制剂及其立体异构体、或其药学上可接受的盐，该抑制PRMT5活性的杂环化合物具有如式(I)所示结构；还进一步提供了包含所述化合物的组合物及其作为PRMT5抑制剂的用途。